Els Van Valckenborgh
Overview
Explore the profile of Els Van Valckenborgh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
2087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Wang J, de Veirman K, De Beule N, Maes K, de Bruyne E, Van Valckenborgh E, et al.
Oncotarget
. 2015 Nov;
6(41):43992-4004.
PMID: 26556857
Exosomes, extracellular nanovesicles secreted by various cell types, modulate the bone marrow (BM) microenvironment by regulating angiogenesis, cytokine release, immune response, inflammation, and metastasis. Interactions between bone marrow stromal cells...
22.
Fristedt Duvefelt C, Lub S, Agarwal P, Arngarden L, Hammarberg A, Maes K, et al.
Oncotarget
. 2015 Jun;
6(24):20621-35.
PMID: 26036313
Despite the introduction of new treatment options for multiple myeloma (MM), a majority of patients relapse due to the development of resistance. Unraveling new mechanisms underlying resistance could lead to...
23.
de Veirman K, Van Ginderachter J, Lub S, De Beule N, Thielemans K, Bautmans I, et al.
Oncotarget
. 2015 Apr;
6(12):10532-47.
PMID: 25871384
Myeloid-derived suppressor cells (MDSC) are contributing to an immunosuppressive environment by their ability to inhibit T cell activity and thereby promoting cancer progression. An important feature of the incurable plasma...
24.
Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E, et al.
Oncotarget
. 2015 Feb;
6(5):3319-34.
PMID: 25669970
Histone deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitors (DNMTi) are in early clinical development for multiple myeloma (MM) therapy. Despite all encouraging pre-clinical data, clinical activity of HDACi and DNMTi...
25.
de Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, de Bruyne E, Menu E, et al.
Front Oncol
. 2014 Dec;
4:349.
PMID: 25538893
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature myeloid cells that accumulate during pathological conditions such as cancer and are associated with a poor clinical outcome. MDSC expansion...
26.
Nur H, Rao L, Frassanito M, De Raeve H, Ribatti D, Mfopou J, et al.
Br J Haematol
. 2014 Aug;
167(5):651-63.
PMID: 25142285
Tumour pathogenesis in multiple myeloma (MM) correlates with a high vascular index. Therefore, targeting angiogenesis is an important therapeutic tool to reduce MM progression. This study aimed to investigate the...
27.
The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
Bieghs L, Lub S, Fostier K, Maes K, Van Valckenborgh E, Menu E, et al.
Oncotarget
. 2014 Jul;
5(22):11193-208.
PMID: 25008202
The ABT-analogous 737, 263 and 199 are BH3 mimetics showing potent anti-myeloma (MM) activity, but only on defined molecular subgroups of MM patients presenting a Bcl-2high/Mcl-1low profile. IGF-1 is a...
28.
de Veirman K, Rao L, de Bruyne E, Menu E, Van Valckenborgh E, Van Riet I, et al.
Cancers (Basel)
. 2014 Jul;
6(3):1363-81.
PMID: 24978438
Cancer associated fibroblasts (CAFs) comprise a heterogeneous population that resides within the tumor microenvironment. They actively participate in tumor growth and metastasis by production of cytokines and chemokines, and the...
29.
Wang J, Hendrix A, Hernot S, Lemaire M, de Bruyne E, Van Valckenborgh E, et al.
Blood
. 2014 Jun;
124(4):555-66.
PMID: 24928860
The interplay between bone marrow stromal cells (BMSCs) and multiple myeloma (MM) cells performs a crucial role in MM pathogenesis by secreting growth factors, cytokines, and extracellular vesicles. Exosomes are...
30.
Maes K, De Smedt E, Lemaire M, De Raeve H, Menu E, Van Valckenborgh E, et al.
Oncotarget
. 2014 May;
5(10):3115-29.
PMID: 24833108
DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi) are under investigation for the treatment of cancer, including the plasma cell malignancy multiple myeloma (MM). Evidence exists that DNA damage...